

## Case Study – SVDK

1. A 58 year old male was hiking through dense bushland in the Blue Mountains when he felt a sharp sting on his right leg. He continued walking for a while before noticing some swelling and pain around what looked like a possible snake bite on his leg. A few hours later the man started experiencing abdominal pain, nausea and vomiting and made his way to the closest emergency department. A swab was taken at the sight of the wound and sent to the laboratory.

*Read the package insert below for the Snake Venom Detection Kit used to analyse the swab:*



# SNAKE BITE MANAGEMENT

**CALL AN AMBULANCE ON 000**



## STEP 1

**Place wound dressing on the bite site.**

Do not wash venom off the skin as it may assist in snake identification.



## STEP 2

**Immediately apply firm pressure on the bandage.**

Apply a further pressure bandage commencing at toes or fingers of the bitten limb and extending upward covering as much of the limb as possible.

**BANDAGE SHOULD BE KEPT FIRM. KEEP THE BODY AND LIMB AS STILL AS POSSIBLE. DO NOT ELEVATE LIMB.**



## STEP 3

**Immobilise the limb.**

After applying the pressure bandage immobilise the limb by binding a splint to it (e.g. a piece of timber, other leg etc.) If the bite is on the forearm put the splinted forearm in a sling.

**CASUALTY MUST STAY CALM , KEEP LIMB STILL AND WAIT FOR EVACUATION.**

Leave the bandage in place until medical aid arrives and check circulation at regular intervals.



[www.firstaidae.com.au](http://www.firstaidae.com.au)



- Snake venom in an envenomated patient will be neutralised and undetectable after adequate amounts of the appropriate antivenom is administered. This effect should be recognised if SVDK samples are collected and tested after the administration of antivenom. Venom will become undetectable in blood and serum samples collected after sufficient antivenom is administered. Venom will also cease to be excreted in urine collected after sufficient antivenom is administered. This means that it is likely that urine samples will become negative, depending on the patient's urine output and next urine voiding event.

Table 1 lists Monovalent snake antivenoms available from Seqirus, which are indicated for the treatment of patients who exhibit systemic envenoming following bites by identified snake species. POLYVALENT SNAKE ANTIVENOM should not be used when the snake has been identified, as appropriate monovalent antivenom provides similar neutralisation of the venom without introducing the larger amounts of equine protein present in the polyvalent product.


TABLE 1

Antivenom	Registered indication for treatment of envenoming by the following Snakes
TIGER SNAKE ANTIVENOM	Tiger Snakes ( <i>Notechis</i> spp) Copperhead Snakes ( <i>Austrolopsis</i> spp) Black Snakes ( <i>Pseudochis</i> spp)*
BROWN SNAKE ANTIVENOM	Brown Snakes ( <i>Pseudonaja</i> spp)
BLACK SNAKE ANTIVENOM	King Brown or Mulga Snake ( <i>Pseudochis australis</i> )*
DEATH ADDER ANTIVENOM	Death Adder ( <i>Acanthophis</i> spp)
TAIPAN ANTIVENOM	Taipan ( <i>Oxyuranus</i> spp)

\* BLACK SNAKE ANTIVENOM is the preferred treatment of bites by a King Brown or Mulga Snake. Specialist advice should be sought for treatment of bites by other members of the Black Snake genus *Pseudochis*.

#### SVDK Template

- Tiger Snake Immunotype  
Tiger Snake Antivenom Indicated
- Brown Snake Immunotype  
Brown Snake Antivenom Indicated
- Black Snake Immunotype  
Black Snake Antivenom Indicated
- Death Adder Immunotype  
Death Adder Antivenom Indicated
- Taipan Immunotype  
Taipan Antivenom Indicated
- Negative Control
- Positive Control
- Blank Well (Not Used)



#### LIMITATIONS OF PROCEDURE

- Warning: Possible Equivocal reactions from Bite Site Swab Specimens.** Bite site specimens containing extremely high levels of snake venom may give equivocal results, even though the test is performed according to the instructions detailed in this product leaflet. Testing at Seqirus has demonstrated that the SVDK assay can be overwhelmed by venom levels exceeding 1mg/mL (1 million times the minimum limit of detection) leading to a reduction in signal strength in the target well and increased cross-reactivity in the other wells. Please note that this will only occur with bite site samples in exceptional circumstances, where large amounts of venom are present. Care should therefore be taken not to swab large amounts of snake venom from the skin surrounding a bite site.

While we recommend that the bite site swab as the sample most likely to give a useful result, urine, blood or a dilution of the bite site swab should be tested if the above effect is suspected. To dilute bite site samples add 1 drop of the diluted specimen to an unused Yellow Sample Diluent vial, mix thoroughly and test in parallel with the undiluted specimen according to the kit instructions above.

- A blood sample should only be used if a bite site or urine specimen is not available. Erroneous reactions resulting in an invalid assay may occur if a whole blood specimen is tested.
- Insufficient washing during Step 5 may cause erroneous results.
- Strict adherence to the 10 minute observation period after addition of the Chromogen and Peroxide Solutions is essential.
- Not all snake venoms are reliably detected by the SVDK. The SVDK is designed to detect venom from snakes belonging to the five land based medically important immunotypes (Tiger Snake, Brown Snake, Black Snake, Death Adder and Taipan). There are many other types of snakes in Australia and PNG and many of these can be venomous.

#### PRECAUTIONS

- For in vitro diagnostic use only.
- The material from which this product was derived is from non-human sources; there is no risk of HIV or HBsAg infection. However, good laboratory practice requires safe handling procedures are used. Caution: All human and animal fluids and tissues should be handled as potentially infectious.
- Yellow Sample Diluent (YSD) contains Thiomersal 0.01% w/v as a preservative. Peroxide Solution contains hydrogen peroxide. Chromogen Solution contains organic solvents Di-methyl Formamide (DMF) and Tetramethylbenzidine (TMB), thus avoid contact with skin. If Chromogen Solution comes into contact with skin wash the affected area with copious quantities of water and seek medical attention. Users should take appropriate precautions when handling and discarding these reagents.
- Kits are issued with an expiry date beyond which the contents must not be used.
- It is important to keep the product leaflet, strip holder, Chromogen Solution and Peroxide Solution as these will be needed in subsequent tests. Do not discard these kit materials until all 3 tests have been conducted.

#### STORAGE CONDITIONS

Store at 2° to 8°C (Refrigerate. Do Not Freeze). Protect From Light. Due to the critical nature of the SVDK test performance, kits subject to storage conditions outside of specification should not be used to test clinical samples. Such kits should be discarded and replaced or used for testing practice or demonstration only.

#### REFERENCES

- Can JC, Mousal AV, Shepherd JM, Drane DP, Jones SL. A novel format for a rapid sandwich ELISA and its application to the identification of snake venoms. *J Immunol Methods* 1992; 146: 273-318.
- Williams D, et al. Venomous Bites and Stings in Papua New Guinea. *KIRU Melbourne* 2005.
- Jelenc GA, Tweed C, Lynch D, Celestia T, Bush B, Michalopoulos N. Cross reactivity between venomous, mildly venomous, and nonvenomous snake venoms with the Commonwealth Serum Laboratories Venom Detection Kit. *Emergency Medicine Australasia*. 2004; 16: 459-464.
- Stevenson J, Winkel K, Carroll T, Williamson NA, Ignjatovic V, Fung K, Paredi AW, Fry BG. The molecular basis of cross-reactivity in the Australian Snake Venom Detection Kit (ASVDK). *Toxicon*. 2007; 50(8): 1041-1052.
- White J. A clinician's guide to Australian venomous bites and stings: incorporating the updated CSL Antivenom Handbook. Seqirus, Melbourne, 2013.

#### Further Information and Assistance


SVDK Technical inquiries and requests for further information relating to the SVDK can be made to Seqirus Medical Information:  
Telephone: 1800 642 865 (within Australia) or +61 3 9389 1932 (from outside Australia)  
Website: [www.seqirus.com.au](http://www.seqirus.com.au)

Small reaction strip	IPV	In vitro diagnostic device	CEP	CE mark	Impedance method	Manufacturer	ASVT	Batch code
Health claim	Health claim							

Seqirus Pty Ltd  
63 Poplar Road, Parkville, Victoria, 3052 Australia  
ABN: 26 160 735 035 Phone +61 3 9389 2000 Fax +61 3 9389 1874

Seqirus is a trademark of Seqirus UK Limited or its affiliates.


2. The following colour reactions occurred in the wells 1-7 over the 10 minute observation period:



2 minutes



5 minutes



7 minutes



10 minutes


3. Interpreting the results above, consider the following options:

i) What is the clinical interpretation?

- a) This result is not indicative of a snakebite.
- b) This result does not exclude snake bite – laboratory tests and clinical findings need to be considered.
- c) This result is good evidence of a snakebite if supported by laboratory tests and clinical findings.
- d) This result indicates unequivocal evidence of snakebite envenoming.
- e) No interpretation offered.

ii) What is the snake venom immunotype (if any) detected?

- a) Tiger Snake Immunotype
- b) Brown Snake Immunotype
- c) Black Snake Immunotype
- d) Death Adder Immunotype
- e) Taipan Immunotype



4. The patient was also found to have the following laboratory findings:

**Coagulation;** patient not reported to be on any anticoagulant therapy.

INR: 1.7

APTT: 50.4s

Fib: 4.0 g/L


TCT: 23s

D-Dimer: 0.54 mg/L

### Cardiac Enzymes

Troponin I: 4 ng/L

Creatine Kinase: 1040 units/L



5. Considering the clinical, and now the additional laboratory findings, what are the clinical findings?

a) Venom detection result, considered in conjunction with the clinical findings and initial blood test results, excludes significant envenoming at this time.

b) Venom detection result, considered in conjunction with the clinical findings and initial blood test results, indicates a defibrination type coagulopathy (Venom Induced Consumptive Coagulopathy or VICC).

c) Venom detection result, considered in conjunction with the clinical findings and initial blood test results, indicates a mild venom-induced anticoagulant type coagulopathy.

d) Venom detection result, considered in conjunction with the clinical findings and initial blood test results, indicates and envenoming which is **NOT** consistent with a defibrination type coagulopathy (Venom Induced Consumptive Coagulopathy or VICC) or venom-induced anticoagulant type coagulopathy.

6. Considering the clinical, and now the additional laboratory findings, what is the snake most likely involved?

*Tiger Snake Immunotype*

- a) Tiger Snake
- b) Copperhead Snake
- c) Rough Scaled Snake

*Brown Snake Immunotype*

- d) Brown Snake
- e) Dugite Snake
- f) Gwardar Snake

*Black Snake Immunotype*

- g) King Brown Snake
- h) Papuan Black Snake
- i) Red Bellied Black Snake
- j) Spotted Black (or Blue) Snake
- k) Butler's Snake
- l) Pigmy Mulga Snake
- m) Collett's Snake

*Death Adder Immunotype*

- n) Common Death Adder
- o) Northern Death Adder
- p) Desert Death Adder
- q) Pilbara Death Adder

*Taipan Immunotype*

- r) Taipan
- s) Inland Taipan
- t) Papuan Taipan



7. What anti-venom is indicated?

- a) None
- b) Brown Snake antivenom
- c) Tiger Snake antivenom
- d) Black Snake antivenom
- e) Death Adder antivenom
- f) Taipan antivenom